Assessing safety in clinical trials - New podcast out now

Research / 29 June 2023

Medicine safety monitoring applies to all aspects of drug development, but how much is it impacted by patient diversity and study type in clinical trials?


Medicine safety monitoring is important in every stage of drug development, from pre-marketing clinical trials to post-marketing analyses. Yet, certain factors in their design can greatly impact its effectiveness, such as the diversity of the study population, or the complexity of its methodology.

All this and more is discussed in the latest Drug Safety Matters podcast episode, where Marianne Lunzer from AGES and Sanja Prpić from HALMED, review the pros and cons of various study types and the importance of testing medicines on diverse populations, as well as how pre and post-marketing studies are linked to give a more comprehensive picture of patient safety.

Subscribe by visiting the Drug Safety Matters website or listen to the podcast here:

You may also like


When medicines change our behaviour – New podcast out now

Adverse effects to medicines are not just physical in nature, but can manifest as behavioural side-effects too. How do we diagnose and treat these complex ADRs?

Research / 02 May 2024

Updating our approach to study adverse reactions

The traditional “drug-event combination” approach is too simplistic for complex side effects such as behavioural changes. We must adjust our methodology to address this intricacy.

Research / 29 May 2024

Looking beyond age to understand adverse reaction risk in older patients

When it comes to pharmacovigilance in older patients, age alone is insufficient as a measure of adverse reaction risk. Here is what we should consider instead.

Research / 13 May 2024

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more